FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982210149> ?p ?o ?g. }

• W2982210149 endingPage "S935" @default.
• W2982210149 startingPage "S934" @default.
• W2982210149 abstract "Abstract Background SOT recipients are an ideal population in which to study the impact of new antibiotics, since they are particularly dependent upon drug activity to clear infections. In 3/15, FDA approved CAZ-AVI, the first new anti-CRE agent to arrive in the clinic. Our objective was to determine whether CAZ-AVI improves short- and long-term outcomes of CRE-infected SOT recipients. Methods We performed a retrospective study of SOT recipients infected with CRE since 2012, who were treated with CAZ-AVI or salvage agents for ≥ 3 days. Results 35 CRE-infected SOT recipients (14 liver, 11 lung, 6 kidney, 3 intestine, 1 heart) with bacteremia (20), pneumonia (11), intra-abdominal abscess (3) and soft-tissue infection/osteomyelitis (1) were enrolled. 16 and 19 patients (pts) were treated with CAZ-AVI and salvage agents, respectively. Types of infection or SOT, APACHE II and McCabe scores did not differ significantly between patients treated with CAZ-AVI or salvage agents. 30- and 90-d mortality rates were significantly lower among SOT recipients treated with CAZ-AVI (0% and 6%, respectively) compared with salvage agents (26% and 37%; P = 0.049 and 0.047). Among patients who survived 90 days, recurrent CRE infections were diagnosed in 53% and 17% of those treated with CAZ-AVI and a salvage regimen, respectively (P = 0.10). Median time from end of therapy for the 1st CRE infection to recurrent infection was 116 days (max 1,242) and 361 days (max 799) for CAZ-AVI and salvage regimens, respectively. Survival and recurrence-free survival were greater for treatment with CAZ-AVI and salvage agents, respectively, as measured by Kaplan–Meier (Figures). CAZ-AVI resistance developed in 37% (n = 3) of patients with recurrent infections. Recurrent isolates were genetically indistinguishable from parent isolates by core genome SNP phylogeny (< 15 SNP). Conclusion CAZ-AVI significantly reduced short-term mortality among SOT recipients with CRE infections compared with salvage regimens, but was limited by recurrent infections and emergence of resistance. The same strains caused recurrent and initial infections, suggesting that CAZ-AVI did not eliminate CRE from GI sites that serve as sources of recurrence. Optimizing outcomes in SOT recipients with CRE infections will require new agents like CAZ-AVI, and strategies to eliminate long-term colonization. Disclosures All authors: No reported disclosures." @default.
• W2982210149 created "2019-11-01" @default.
• W2982210149 creator A5024677215 @default.
• W2982210149 creator A5036789267 @default.
• W2982210149 creator A5090336151 @default.
• W2982210149 creator A5091295958 @default.
• W2982210149 date "2019-10-01" @default.
• W2982210149 modified "2023-09-23" @default.
• W2982210149 title "2667. Does Ceftazidime–Avibactam (CAZ-AVI) Improve Short- and Long-Term Outcomes Among Solid-Organ Transplant (SOT) Recipients with Carbapenem-Resistant Enterobacteriaceae (CRE) Infections?" @default.
• W2982210149 doi "https://doi.org/10.1093/ofid/ofz360.2345" @default.
• W2982210149 hasPublicationYear "2019" @default.
• W2982210149 type Work @default.
• W2982210149 sameAs 2982210149 @default.
• W2982210149 citedByCount "2" @default.
• W2982210149 countsByYear W29822101492021 @default.
• W2982210149 crossrefType "journal-article" @default.
• W2982210149 hasAuthorship W2982210149A5024677215 @default.
• W2982210149 hasAuthorship W2982210149A5036789267 @default.
• W2982210149 hasAuthorship W2982210149A5090336151 @default.
• W2982210149 hasAuthorship W2982210149A5091295958 @default.
• W2982210149 hasBestOaLocation W29822101491 @default.
• W2982210149 hasConcept C126322002 @default.
• W2982210149 hasConcept C141071460 @default.
• W2982210149 hasConcept C2775933652 @default.
• W2982210149 hasConcept C2776685102 @default.
• W2982210149 hasConcept C2776694085 @default.
• W2982210149 hasConcept C2776968632 @default.
• W2982210149 hasConcept C2777406300 @default.
• W2982210149 hasConcept C2777637488 @default.
• W2982210149 hasConcept C2777914695 @default.
• W2982210149 hasConcept C2779443120 @default.
• W2982210149 hasConcept C2780775027 @default.
• W2982210149 hasConcept C2781413609 @default.
• W2982210149 hasConcept C2908647359 @default.
• W2982210149 hasConcept C501593827 @default.
• W2982210149 hasConcept C523546767 @default.
• W2982210149 hasConcept C54355233 @default.
• W2982210149 hasConcept C71924100 @default.
• W2982210149 hasConcept C86803240 @default.
• W2982210149 hasConcept C89423630 @default.
• W2982210149 hasConcept C90924648 @default.
• W2982210149 hasConcept C99454951 @default.
• W2982210149 hasConceptScore W2982210149C126322002 @default.
• W2982210149 hasConceptScore W2982210149C141071460 @default.
• W2982210149 hasConceptScore W2982210149C2775933652 @default.
• W2982210149 hasConceptScore W2982210149C2776685102 @default.
• W2982210149 hasConceptScore W2982210149C2776694085 @default.
• W2982210149 hasConceptScore W2982210149C2776968632 @default.
• W2982210149 hasConceptScore W2982210149C2777406300 @default.
• W2982210149 hasConceptScore W2982210149C2777637488 @default.
• W2982210149 hasConceptScore W2982210149C2777914695 @default.
• W2982210149 hasConceptScore W2982210149C2779443120 @default.
• W2982210149 hasConceptScore W2982210149C2780775027 @default.
• W2982210149 hasConceptScore W2982210149C2781413609 @default.
• W2982210149 hasConceptScore W2982210149C2908647359 @default.
• W2982210149 hasConceptScore W2982210149C501593827 @default.
• W2982210149 hasConceptScore W2982210149C523546767 @default.
• W2982210149 hasConceptScore W2982210149C54355233 @default.
• W2982210149 hasConceptScore W2982210149C71924100 @default.
• W2982210149 hasConceptScore W2982210149C86803240 @default.
• W2982210149 hasConceptScore W2982210149C89423630 @default.
• W2982210149 hasConceptScore W2982210149C90924648 @default.
• W2982210149 hasConceptScore W2982210149C99454951 @default.
• W2982210149 hasIssue "Supplement_2" @default.
• W2982210149 hasLocation W29822101491 @default.
• W2982210149 hasLocation W29822101492 @default.
• W2982210149 hasOpenAccess W2982210149 @default.
• W2982210149 hasPrimaryLocation W29822101491 @default.
• W2982210149 hasRelatedWork W2435544242 @default.
• W2982210149 hasRelatedWork W2437593726 @default.
• W2982210149 hasRelatedWork W2483207560 @default.
• W2982210149 hasRelatedWork W2618911885 @default.
• W2982210149 hasRelatedWork W2896701123 @default.
• W2982210149 hasRelatedWork W2971663956 @default.
• W2982210149 hasRelatedWork W2975061016 @default.
• W2982210149 hasRelatedWork W2981943845 @default.
• W2982210149 hasRelatedWork W3045087012 @default.
• W2982210149 hasRelatedWork W3169832973 @default.
• W2982210149 hasVolume "6" @default.
• W2982210149 isParatext "false" @default.
• W2982210149 isRetracted "false" @default.
• W2982210149 magId "2982210149" @default.
• W2982210149 workType "article" @default.